Tractive

An analyst slashed the price target on Capricor Therapeutics (CAPR) stock by 86%, a dramatic downgrade for the biotech. Retail investors, however, are pushing back, arguing the current share price still offers an attractive risk-reward setup despite the sharply reduced target. The split between Wall Street caution and retail bullishness is driving debate over the stock's near-term prospects.